Skip to main content
Livermore
Livermore
ZHEN

Kynam Capital Management, LP

SEC CIK
0001907884
Latest filing
Aug 14, 2026

The latest 13F from Kynam Capital Management, LP covers Q2 2026 (filed Aug 14, 2026): 32 long positions worth $1.81B. The top 10 holdings make up 72.7% of the portfolio, and the largest is Celldex Therapeutics, Inc. (CLDX) at 10.9%. Livermore has 19 filings on Form 13F from this institution, going back to Q4 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
4
Est. +$35.1M
Added
12
Est. +$233.6M
Reduced
7
Est. −$118.5M
Sold out
8
Est. −$131.1M

Top 5 holdings

Share of this quarter's portfolio value

  1. CLDXCelldex Therapeutics, Inc.
    10.9%$198.1MHistory
  2. SNDXSyndax Pharmaceuticals Inc
    9.7%$176.0MHistory
  3. PCVXVaxcyte, Inc.
    9.4%$169.9MHistory
  4. COGTCogent Biosciences, Inc.
    7.8%$141.9MHistory
  5. VERAVera Therapeutics, Inc.
    6.9%$124.0MHistory

Biggest buys

New and added positions, by estimated amount bought

  1. VRDNViridian Therapeutics, Inc.
    +$75.5MAddedHistory
  2. LEGNLegend Biotech Corp
    +$41.2MAddedHistory
  3. RLAYRelay Therapeutics, Inc.
    +$35.1MAddedHistory
  4. CTMXCytomX Therapeutics, Inc.
    +$25.1MAddedHistory
  5. TVTXTravere Therapeutics, Inc.
    +$24.5MAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. VRDNViridian Therapeutics, Inc.
    +3.65 pp2.9% → 6.6%History
  2. TVTXTravere Therapeutics, Inc.
    +3.32 pp3.0% → 6.3%History
  3. LEGNLegend Biotech Corp
    +2.98 pp1.8% → 4.8%History
  4. RLAYRelay Therapeutics, Inc.
    +2.51 pp0.9% → 3.4%History
  5. URGNUroGen Pharma Ltd.
    +2.39 pp2.6% → 5.0%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. KALVKalVista Pharmaceuticals, Inc.
    −$36.7MSold outHistory
  2. APLSApellis Pharmaceuticals, Inc.
    −$33.2MSold outHistory
  3. BCRXBiocryst Pharmaceuticals Inc
    −$31.6MReducedHistory
  4. BEAMBeam Therapeutics Inc.
    −$28.9MReducedHistory
  5. VERAVera Therapeutics, Inc.
    −$21.8MReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. KALVKalVista Pharmaceuticals, Inc.
    −2.33 pp2.3% → 0.0%History
  2. APLSApellis Pharmaceuticals, Inc.
    −2.11 pp2.1% → 0.0%History
  3. BCRXBiocryst Pharmaceuticals Inc
    −2.04 pp3.4% → 1.4%History
  4. COGTCogent Biosciences, Inc.
    −2.02 pp9.9% → 7.8%History
  5. VERAVera Therapeutics, Inc.
    −1.82 pp8.7% → 6.9%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$1.81B
+$233.9M (+14.8%) vs. prior quarter
Positions
32
−4 vs. prior quarter
Top 10 concentration
72.7%
Top 10 as share of value
Turnover
14.7%
Q2 2026, one quarter
Average holding period
13.0 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q4 2021), so positions held before then are understated.

13F filings by quarter

19 quarters, going back to Q4 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $1.81B (Q2 2026)

Q4 2021: $187.1MQ1 2022: $307.6MQ2 2022: $387.6MQ3 2022: $473.3MQ4 2022: $651.9MQ1 2023: $773.0MQ2 2023: $652.5MQ3 2023: $601.6MQ4 2023: $883.6MQ1 2024: $898.9MQ2 2024: $955.2MQ3 2024: $1.29BQ4 2024: $1.52BQ1 2025: $1.17BQ2 2025: $928.8MQ3 2025: $1.34BQ4 2025: $1.54BQ1 2026: $1.58BQ2 2026: $1.81B
Q4 2021Q2 2026
13F filings of Kynam Capital Management, LP by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 202632$1.81BCLDXSNDXPCVXvs. Q1 2026SEC
Q1 2026May 15, 202636$1.58BSNDXCLDXPCVXvs. Q4 2025SEC
Q4 2025Feb 17, 202635$1.54BCOGTVERASNDXvs. Q3 2025SEC
Q3 2025Nov 14, 202535$1.34BCLDXSNDXVERAvs. Q2 2025SEC
Q2 2025Aug 14, 202531$928.8MCLDXPCVXVERAvs. Q1 2025SEC
Q1 2025May 15, 202531$1.17BNTRAPCVXCLDXvs. Q4 2024SEC
Q4 2024Feb 14, 202529$1.52BNTRAPCVXCLDXvs. Q3 2024SEC
Q3 2024Nov 14, 202424$1.29BNTRAPCVXCLDXvs. Q2 2024SEC
Q2 2024Aug 14, 202422$955.2MNTRACLDXSNDXvs. Q1 2024SEC
Q1 2024May 15, 202421$898.9MNTRASNDXCLDXvs. Q4 2023SEC
Q4 2023Feb 14, 202423$883.6MNTRASNDXCLDXvs. Q3 2023SEC
Q3 2023Nov 14, 202327$601.6MNTRACLDXPCVXvs. Q2 2023SEC
Q2 2023Aug 14, 202323$652.5MNTRACLDXSNDXvs. Q1 2023SEC
Q1 2023May 15, 202334$773.0MNTRAHZNPSNDXvs. Q4 2022SEC
Q4 2022Feb 14, 202331$651.9MHZNPNTRACLDXvs. Q3 2022SEC
Q3 2022Nov 14, 202233$473.3MNTRASNDXCLDXvs. Q2 2022SEC
Q2 2022Aug 15, 202231$387.6MGBTSNDXNTRAvs. Q1 2022SEC
Q1 2022May 13, 202231$307.6MGBTNTRASNDXvs. Q4 2021SEC
Q4 2021Feb 14, 202230$187.1MGBTXENESNDX–SEC

13D and 13G filings

Companies where Kynam Capital Management, LP reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

7 companies, largest stake first.

Companies where Kynam Capital Management, LP owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
BNRBurning Rock Biotech Ltd13G/A13.97%0 shares+2.96 ppfrom 11.01%Feb 10, 20233 filingsMay 15, 2026SEC
SNDXSyndax Pharmaceuticals Inc13G/A9.98%8.52M shares–Feb 14, 20251 filingFeb 14, 2025SEC
CTMXCytomX Therapeutics, Inc.13G/A9.96%0 shares+3.06 ppfrom 6.90%Mar 4, 20263 filingsAug 14, 2026SEC
CLDXCelldex Therapeutics, Inc.13G/A6.78%0 shares−1.99 ppfrom 8.77%Feb 14, 20254 filingsAug 14, 2026SEC
VRDNViridian Therapeutics, Inc.13G/A5.70%0 shares+4.16 ppfrom 1.54%May 15, 20253 filingsAug 14, 2026SEC
CGEMCullinan Therapeutics, Inc.13G5.27%3.11M sharesNewMar 4, 20261 filingMar 4, 2026SEC
STROSutro Biopharma, Inc.13G/A5.27%0 shares−1.17 ppfrom 6.44%May 15, 20252 filingsMay 15, 2026SEC

Latest filings

30 filings on file made by Kynam Capital Management, LP or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by Kynam Capital Management, LP
CompanyFiled (ET)FormStakeChangeEvent dateFiling
VRDNViridian Therapeutics, Inc.Aug 14, 202612:17 PM ET13G/A5.70%0 shares+4.16 ppfrom 1.54%Jun 30, 2026SEC
VERAVera Therapeutics, Inc.Aug 14, 202612:16 PM ET13G/A4.01%0 shares−1.36 ppfrom 5.37%Below 5%Jun 30, 2026SEC
CTMXCytomX Therapeutics, Inc.Aug 14, 202612:11 PM ET13G/A9.96%0 shares+3.06 ppfrom 6.90%Jun 30, 2026SEC
CLDXCelldex Therapeutics, Inc.Aug 14, 202612:09 PM ET13G/A6.78%0 shares−1.99 ppfrom 8.77%Jun 30, 2026SEC
BNRBurning Rock Biotech LtdMay 15, 20264:01 PM ET13G/A13.97%0 shares+2.96 ppfrom 11.01%Mar 31, 2026SEC
CTMXCytomX Therapeutics, Inc.May 15, 20264:01 PM ET13G/A6.90%0 shares+1.61 ppfrom 5.29%Mar 31, 2026SEC
CLDXCelldex Therapeutics, Inc.May 15, 20264:01 PM ET13G/A8.77%0 shares−1.02 ppfrom 9.79%Mar 31, 2026SEC
STROSutro Biopharma, Inc.May 15, 20264:01 PM ET13G/A5.27%0 shares−1.17 ppfrom 6.44%Mar 31, 2026SEC
CTMXCytomX Therapeutics, Inc.Mar 4, 20263:18 PM ET13G5.29%8.97M sharesNewDec 31, 2025SEC
CGEMCullinan Therapeutics, Inc.Mar 4, 20263:16 PM ET13G5.27%3.11M sharesNewDec 31, 2025SEC
VRDNViridian Therapeutics, Inc.Feb 17, 202612:52 PM ET13G/A1.54%1.47M shares−4.22 ppfrom 5.76%Below 5%Dec 31, 2025SEC
ENGNenGene Therapeutics Inc.Feb 17, 202612:46 PM ET13G/A2.23%1.49M shares−7.57 ppfrom 9.80%Below 5%Dec 31, 2025SEC
COGTCogent Biosciences, Inc.Feb 17, 202612:43 PM ET13G/A4.33%6.17M shares−1.21 ppfrom 5.54%Below 5%Dec 31, 2025SEC
BNRBurning Rock Biotech LtdNov 14, 202512:37 PM ET13G/A11.01%994.9K shares–Sep 30, 2025SEC
COGTCogent Biosciences, Inc.Nov 14, 202512:36 PM ET13G/A5.54%7.89M shares–Sep 30, 2025SEC
VERAVera Therapeutics, Inc.Aug 14, 202511:00 AM ET13G5.37%3.43M shares–Jun 30, 2025SEC
CLDXCelldex Therapeutics, Inc.May 15, 202511:48 AM ET13G/A9.79%6.50M shares+2.16 ppfrom 7.63%Mar 31, 2025SEC
VRDNViridian Therapeutics, Inc.May 15, 202511:44 AM ET13G5.76%0 sharesNewMar 31, 2025SEC
STROSutro Biopharma, Inc.May 15, 202511:39 AM ET13G6.44%0 sharesNewMar 31, 2025SEC
TSVT2seventy bio, Inc.Mar 17, 202510:54 AM ET13G/A0.00%0 shares–Below 5%Mar 11, 2025SEC